[go: up one dir, main page]

US20100028314A1 - Bacillus Amyloliquefaciens Strain - Google Patents

Bacillus Amyloliquefaciens Strain Download PDF

Info

Publication number
US20100028314A1
US20100028314A1 US12/511,499 US51149909A US2010028314A1 US 20100028314 A1 US20100028314 A1 US 20100028314A1 US 51149909 A US51149909 A US 51149909A US 2010028314 A1 US2010028314 A1 US 2010028314A1
Authority
US
United States
Prior art keywords
bacillus amyloliquefaciens
amyloliquefaciens strain
bacteria
preferred
microorganisms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/511,499
Other languages
English (en)
Inventor
Amy Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Priority to US12/511,499 priority Critical patent/US20100028314A1/en
Assigned to NOVOZYMES A/S reassignment NOVOZYMES A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SNYDER, AMY
Publication of US20100028314A1 publication Critical patent/US20100028314A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A01N63/22—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus

Definitions

  • the present application refers to deposited microorganisms.
  • the contents of the deposited microorganisms are fully incorporated herein by reference.
  • the present invention relates to Bacillus amyloliquefaciens strain NRRL B-50154 and methods and compositions for preventing and/or reducing biofilm formation on surfaces and/or planktonic proliferation in aqueous environments, especially in domestic/household and industrial settings.
  • the present invention also relates to deodorizing liquid compositions which are designed to be applied in the areas of pet care, toilet care, carpet care, and garbage collections or processes, management of industrial wastes, including sludge processing, landfill and composting, and odor control of livestock production processes and other organic wastes.
  • the present invention also relates to compositions for cleaning objects such as drains or outlet pipes for waste water, sewers from, e.g., homes or industrial enterprises, vehicles, holding tanks, septic tanks, etc.
  • Biofilm formation and planktonic proliferation by undesired microorganisms are well known phenomena in domestic as well as industrial settings. For instance, toilet bowls harbor undesirable bacteria on surfaces and in solution that can contribute to a noticeably fouled appearance of the bowl. Further, the presence of undesired microorganisms in the bowl may cause dispersion of aerosols when flushing. Massive biofilm formation and planktonic proliferation in water systems, e.g., pipes, pumps and vessels, are known to cause health care risks, corrosion, and aesthetic problems.
  • Preventing or reducing biofilm formation and/or planktonic proliferation by undesirable microorganisms traditionally requires the use of dispersants, surfactants, enzymes, microbes, antimicrobial agents, biocides, boil-out procedures, and/or chemicals.
  • U.S. Pat. No. 5,171,591 concerns controlling or eliminating undesired bacteria in or on certain food or food contact surfaces using parasitic bacteria of the genus Bdellovibrio.
  • U.S. Pat. No. 5,242,593 concerns a method for reducing the buildup of slime and/or film in water circulation systems by adding non-sessile microbes in single form to the circulating water.
  • U.S. Pat. No. 5,360,517 discloses a process of regulating the growth of the microbial/bacterial flora existing in an aqueous papermaking circuit/process stream comprising introducing an effective disinfectant amount of bacteria of the species Staphylococcus carnosus.
  • U.S. Pat. No. 5,863,882 concerns liquid cleaning and sanitizing formulations comprising a sanitizing composition, viable Bacillus spores, and surfactants capable of reducing four pathogenic microorganisms.
  • AU Patent No. 719544 concerns a method of controlling the number of pathogenic bacteria in a body of water by adding non-pathogenic gram positive bacteria.
  • WO 2006/031554 disclose a method of preventing, removing, reducing or disrupting biofilms on surfaces by contacting said surface with an alpha-amylase derived from a bacterium.
  • WO 2008/021761 discloses compositions comprising and methods of washing laundry or fabrics with Bacillus amyloliquefaciens strain SB3282 (deposited at the American Type Culture Collection (ATCC) under accession number PTA-7543) and one or more ingredients selected from the group of surfactants, hydrotropes, preservatives, fillers, builders, stabilizer, fragrances, anti-redeposition agents, nutrients, biostimulants, and enzymes; or a combination of one or more thereof.
  • ATCC American Type Culture Collection
  • PCT/US2008/057670 discloses methods for preventing and/or reducing biofilm formation on a surface, comprising subjecting said surface to Bacillus amyloliquefaciens strain SB3282.
  • the present invention relates to a biologically pure culture of Bacillus amyloliquefaciens strain NRRL B-50154.
  • Bacillus amyloliquefaciens strain NRRL B-50154 is a bacteriophage-resistant (phage-resistant) variant of Bacillus amyloliquefaciens strain SB3282.
  • phage-resistant phage-resistant
  • Bacillus amyloliquefaciens strain NRRL B-50154 is resistant to such a phage, and therefore maintains growth and realizes the benefits described herein.
  • the present invention also relates to methods and compositions for reducing and/or preventing biofilm formation and/or planktonic proliferation in aqueous environments.
  • Bacillus amyloliquefaciens strain NRRL B-50154 is able to produce amylase, which catalyzes the degradation of the principal chemical components of drain residues, such as starches.
  • This invention also relates to a liquid deodorizing composition
  • a liquid deodorizing composition comprising Bacillus amyloliquefaciens strain NRRL B-50154 in an aqueous solution, e.g., distilled water, tap water, a saline solution or other aqueous solution.
  • the present invention is also directed to a drain opener formulation comprising Bacillus amyloliquefaciens strain NRRL B-50154.
  • the present invention also relates to a sanitizing composition
  • a sanitizing composition comprising Bacillus amyloliquefaciens strain NRRL B-50154 in an aqueous solution.
  • the present invention is directed to a biologically pure culture of Bacillus amyloliquefaciens strain NRRL B-50154.
  • the invention also relates to methods for preventing and/or reducing biofilm formation on a surface comprising subjecting said surface to Bacillus amyloliquefaciens strain NRRL B-50154.
  • biofilm formation means the formation of a slime layer or film by undesired microorganisms on a surface. Biofilm formation is a consequence of growth of undesired microorganisms which attach singly or in colonies to a surface.
  • surface refers to any surface, preferably hard surfaces, which may be prone to biofilm formation and adhesion of microorganisms.
  • contemplated surfaces include hard surfaces made from one or more of the following materials: metal, plastic, rubber, board, glass, wood, paper, concrete, rock, marble, gypsum and ceramic materials, such as porcelain, which optionally are coated, for example, with paint or enamel.
  • soft surfaces include surfaces made of fibers of any kind (e.g., yarns, textiles, vegetable fibers, rock wool, and hair); or any porous surface; skin (human or animal); keratinous materials (e.g., nails); and internal organs (e.g., lungs).
  • Hard surfaces are, for instance, found in bathrooms, e.g., fixtures, sinks, bathtubs, toilet bowls, and rinse water reservoirs; in cooling towers; water treatment plants; water tanks; dairy, food processing plants etc.; chemical or pharmaceutical process plants; or medical devices (e.g., catheters, orthopedic devices, and implants).
  • Biofilm prone surfaces may also be porous surfaces. Porous surfaces can, for instance, be present in filters, e.g., membrane filters.
  • the invention also relates to methods for preventing and/or reducing planktonic proliferation of microorganism(s), comprising subjecting said microorganism(s) in aqueous solution to Bacillus amyloliquefaciens strain NRRL B-50154.
  • planktonic proliferation means growth of undesired microorganisms, preferably undesired bacteria, in an aqueous environment, such as a body of water.
  • the undesired microorganisms typically occur freely in the aqueous environment. Examples of contemplated aqueous environments are rinse water in toilet bowls and cooling water circulated in plants.
  • environments that receive high loads of undesirable microorganisms and nutrients require high doses of mitigating bacteria strains, while environments with low loads of undesirable organisms require lower doses of mitigating bacteria strains.
  • preventing biofilm formation on surfaces or preventing planktonic formation in aqueous environments in general, require lower doses of Bacillus amyloliquefaciens strain NRRL B-50154 than reducing biofilm formation on corresponding surfaces or reducing the number of already existing undesired microorganism(s) in corresponding aqueous environments.
  • a method of the invention can be used for inhibiting growth (i.e., leading to reduced biofilm formation) of one or more undesired microorganisms, preferably bacteria already present on a surface or already present in an aqueous environment.
  • the invention relates to preventing and/or significantly retarding biofilm formation on an essentially clean surface (i.e., surface with essentially no undesired microorganisms) and/or planktonic proliferation in essentially clean water (i.e., aqueous environment containing essentially no undesired microorganisms).
  • Bacillus amyloliquefaciens strain NRRL B-50154 protects the surface and/or aqueous environment against future growth of one or more undesired microorganisms.
  • a method of the invention may result in reduction or even elimination/removal of already existing undesired microorganisms.
  • Bacillus amyloliquefaciens strain NRRL B-50154 may in a preferred embodiment be applied to the surface in question and/or or added to the aqueous environment in question periodically. Periodically means that the method of the invention may be reiterated or repeated over a period of time, e.g., every minute, hour, day, week, month, etc. As mentioned above, the effect may not last for a long period of time.
  • Bacillus amyloliquefaciens strain NRRL B-50154 may require redosing of Bacillus amyloliquefaciens strain NRRL B-50154. For instance, when the surface and aqueous environment is on the inside of a toilet bowl and the rinsing water in the toilet bowl, respectively, redosing may take place (periodically), e.g., with every flushing. Bacillus amyloliquefaciens strain NRRL B-50154 may, for instance, be incorporated into a rim block.
  • a method of the invention may also be carried out by manually and/or mechanically subjecting (i.e., applying or contacting) Bacillus amyloliquefaciens strain NRRL B-50154 or a composition comprising Bacillus amyloliquefaciens strain NRRL B-50154 to the surface in question.
  • undesired microorganisms means microorganisms that may result in an effect considered to be negative on the surface in question and/or in the aqueous environment in question, especially in domestic or industrial settings. Examples of such negative effects include odor, corrosion, pitting, or other degradation of material; infection; staining or otherwise making a surface appear aesthetically unpleasing. Undesired microorganisms also include pathogenic microorganisms, especially pathogenic bacteria.
  • Bacillus amyloliquefaciens strain NRRL B-50154 in an effective amount biofilm formation on surfaces and/or planktonic proliferation in aqueous environments can be reduced and/or prevented.
  • the surface in question prone to biofilm formation may be subjected to Bacillus amyloliquefaciens strain NRRL B-50154 as a preventative measure prior to any biofilm formation/buildup. This results in that significantly less biofilm is formed.
  • Bacillus amyloliquefaciens strain NRRL B-50154 as a preventative measure prior to any biofilm formation/buildup.
  • NRRL B-50154 Bacillus amyloliquefaciens strain NRRL B-50154
  • Examples of undesired microorganisms include those disclosed below.
  • Undesired microorganisms include, but are not limited to, aerobic bacteria or anaerobic bacteria, gram positive and gram negative, fungi (yeast or filamentous fungus), algae, and/or protozoa.
  • Contemplated bacteria include bacteria selected from the group consisting of. Pseudomonas spp.
  • Pseudomonas aeruginosa including Pseudomonas aeruginosa, Azotobacter vinelandii, Escherichia coli, Corynebacterium diphteriae, Clostridium botulinum, Streptococcus spp., Acetobacter, Leuconostoc, Betabacterium, Pneumococcus, Mycobacterium tuberculosis, Aeromonas, Burkholderia, Flavobacterium, Salmonella, Staphylococcus, Vibrio spp., Listeria spp., and Legionella spp.
  • the undesired microorganism is an aerobic bacterium.
  • the aerobic bacterium is an Aeromonas strain.
  • the aerobic bacterium is a Burkholderia strain.
  • the aerobic bacterium is a Flavobacterium strain.
  • the aerobic bacterium is a Microbacterium strain.
  • the aerobic bacterium is a Pseudomonas strain.
  • the aerobic bacterium is a Salmonella strain.
  • the aerobic bacterium is a Staphylococcus strain.
  • the aerobic bacterium is from the family Enterobacteriaceae (including e.g., Escherichia coli ).
  • the aerobic bacterium is Burkholderia cepacia . In another most preferred embodiment, the aerobic bacterium is a Microbacterium imperiale or Mycobacterium tuberculosis . In another most preferred embodiment, the aerobic bacterium is Pseudomonas aeruginosa . In another most preferred embodiment, the aerobic bacterium is Pseudomonas fluorescens . In another most preferred embodiment, the aerobic bacterium is Pseudomonas oleovorans . In another most preferred embodiment, the aerobic bacterium is Pseudomonas pseudoalcaligenes . In another most preferred embodiment, the aerobic bacterium is Salmonella enteritidis . In another most preferred embodiment, the aerobic bacterium is Staphylococcus aureus . In another most preferred embodiment, the aerobic bacterium is Staphylococcus epidermidis.
  • the bacterium is Listeria monocytogenes.
  • the bacteria is Legionella adelaidensis . In another most preferred embodiment the bacteria is Legionella pneumophila . In another most preferred embodiment the bacteria is Legionella feeleii . In another most preferred embodiment the bacteria is Legionella moravica.
  • the bacteria is Vibrio harveyi, Vibrio fischerii , and/or Vibrio alginolyticus.
  • the microorganism is an anaerobic bacterium.
  • the anaerobic bacterium is a Desulfovibrio strain .
  • the anaerobic bacterium is Desulfovibrio desulfuricans.
  • the undesired microorganism is a fungus such as a yeast or filamentous fungus.
  • the yeast is a Candida strain.
  • the yeast is Candida albicans.
  • the invention also relates to a composition
  • a composition comprising Bacillus amyloliquefaciens strain NRRL B-50154.
  • the compositions may be deodorizing liquid compositions which are designed to be applied in the areas of pet care, toilet care, carpet care, and garbage collections or processes, management of industrial wastes, including sludge processing, landfill and composting, and odor control of livestock production processes and other organic wastes.
  • the compositions may also be used for cleaning objects such as drains or outlet pipes for waste water, sewers from, e.g., homes or industrial enterprises, vehicles, holding tanks, septic tanks, etc.
  • effective amount is defined herein as the amount, concentration or dosage of one or more bacteria strains that can reduce and/or prevent biofilm formation caused by undesired microorganisms on a surface and/or reduce and/or prevent planktonic proliferation of undesired microorganisms in an aqueous environment.
  • the actual effective dosage in absolute numbers depends on factors including: the undesired microorganism(s) in question; whether the aim is prevention or reduction; the contact time between the strain(s) or composition comprising said strain(s); other ingredients present, and also the surface or aqueous environment in question.
  • An effective dosage of Bacillus amyloliquefaciens strain NRRL B-50154 is in the range from 1 to 1 ⁇ 10 8 CFU/ml (CFU, colony forming unit), preferably 50 to 1 ⁇ 10 7 CFU/ml. Further, in an embodiment the ratio between the Bacillus amyloliquefaciens strain NRRL B-50154 and the undesired microorganism(s) in question may be between 1:100,000 and 100,000:1 (bacterial strain:undesired microorganism), preferably 1:10,000 to 10,000:1, more preferably 1:1,000 to 1,000:1, more preferably 1:100 to 100:1, even more preferably 1:10 to 10:1.
  • composition may comprise other active and/or inactive ingredients.
  • the surfactants may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic.
  • the surfactant(s) should cause as little harm to the bacteria culture's activity as possible.
  • the surfactants may be present in the composition at a level of from 0.01% to 60% by weight.
  • the composition When included therein the composition usually contains from about 0 to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.
  • an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.
  • the composition When included therein the composition usually contains from about 0 to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine (“glucamides”).
  • a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine (“glucamides”).
  • glucamides N-acyl N-alkyl derivatives of glucosamine
  • composition may comprise one or more enzymes.
  • contemplated enzymes are mentioned in the “Enzymes”-section.
  • ingredients include, but are not limited to, dispersants, stabilizers, anti-microbial agents, fragrances, dyes, and biocides.
  • One or more enzymes may be present in a composition of the invention.
  • Especially contemplated enzymes include alpha-amylases, cellulases, lipases, mannanases, pectate lyases, peroxidases/oxidases, and proteases, or mixtures thereof.
  • proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included.
  • the protease may be a serine protease or a metallo protease, preferably an alkaline microbial protease or a trypsin-like protease.
  • alkaline proteases are subtilisins, especially those derived from Bacillus , e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279).
  • trypsin-like proteases are trypsin (e.g., of porcine or bovine origin) and the Fusarium protease described in WO 89/06270 and WO 94/25583.
  • Examples of useful proteases are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with substitutions in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.
  • Preferred commercially available protease enzymes include ALCALASETM, SAVINASETM, PRIMASETM, DURALASETM, DYRAZYMTM, ESPERASETM, EVERLASETM, POLARZYMETM and KANNASETM, LIQUANASETM (Novozymes A/S), MAXATASETM, MAXACALTM, MAXAPEMTM, PROPERASETM, PURAFECTTM, PURAFECT OxPTM, FN2TM, and FN3TM (Genencor International Inc.).
  • Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from Humicola (synonym Thermomyces ), e.g., from H. lanuginosa ( T. lanuginosus ) as described in EP 258 068 and EP 305 216 or from H. insolens as described in WO 96/13580, a Pseudomonas lipase , e.g., from P. alcaligenes or P. pseudoalcaligenes (EP 218 272), P. cepacia (EP 331 376), P. stutzeri (GB 1,372,034), P.
  • lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202.
  • Preferred commercially available lipase enzymes include LIPOLASETM and LIPOLASE ULTRATM, LIPOZYMETM, and LIPEXTM (Novozymes A/S).
  • Cutinase The method of the invention may be carried out in the presence of cutinase classified in EC 3.1.1.74.
  • cutinase used according to the invention may be of any origin.
  • cutinases are of microbial origin, in particular of bacterial, of fungal or of yeast origin.
  • Cutinases are enzymes which are able to degrade cutin.
  • the cutinase is derived from a strain of Aspergillus , in particular Aspergillus oryzae , a strain of Alternaria , in particular Alternaria brassiciola , a strain of Fusarium , in particular Fusarium solani, Fusarium solani pisi, Fusarium roseum culmorum , or Fusarium roseum sambucium , a strain of Helminthosporum , in particular Helminthosporum sativum , a strain of Humicola , in particular Humicola insolens , a strain of Pseudomonas , in particular Pseudomonas mendocina , or Pseudomonas putida , a strain of Rhizoctonia , in particular Rhizoctonia solani , a strain of Streptomyces , a
  • the cutinase is derived from a strain of Humicola insolens , in particular the strain Humicola insolens DSM 1800.
  • Humicola insolens cutinase is described in WO 96/13580 which is herby incorporated by reference.
  • the cutinase may be a variant, such as one of the variants disclosed in WO 00/34450 and WO 01/92502, which are hereby incorporated by reference.
  • Preferred cutinase variants include variants listed in Example 2 of WO 01/92502, which is hereby specifically incorporated by reference.
  • Preferred commercial cutinases include NOVOZYMTM 51032 (available from Novozymes A/S, Denmark).
  • phospholipase classified as EC 3.1.1.4 and/or EC 3.1.1.32.
  • phospholipase is an enzyme which has activity towards phospholipids.
  • Phospholipids such as lecithin or phosphatidylcholine, consist of glycerol esterified with two fatty acids in an outer (sn-1) and the middle (sn-2) positions and esterified with phosphoric acid in the third position; the phosphoric acid, in turn, may be esterified to an amino-alcohol.
  • Phospholipases are enzymes which participate in the hydrolysis of phospholipids.
  • phospholipases A 1 and A 2 which hydrolyze one fatty acyl group (in the sn-1 and sn-2 position, respectively) to form lysophospholipid
  • lysophospholipase or phospholipase B
  • Phospholipase C and phospholipase D release diacyl glycerol or phosphatidic acid respectively.
  • phospholipase includes enzymes with phospholipase activity, e.g., phospholipase A (A 1 or A 2 ), phospholipase B activity, phospholipase C activity or phospholipase D activity.
  • phospholipase A used herein in connection with an enzyme of the invention is intended to cover an enzyme with Phospholipase A 1 and/or Phospholipase A 2 activity.
  • the phospholipase activity may be provided by enzymes having other activities as well, such as, e.g., a lipase with phospholipase activity.
  • the phospholipase activity may, e.g., be from a lipase with phospholipase side activity.
  • the phospholipase enzyme activity is provided by an enzyme having essentially only phospholipase activity and wherein the phospholipase enzyme activity is not a side activity.
  • the phospholipase may be of any origin, e.g., of animal origin (such as, e.g., mammalian), e.g., from pancreas (e.g., bovine or porcine pancreas), or snake venom or bee venom.
  • animal origin such as, e.g., mammalian
  • pancreas e.g., bovine or porcine pancreas
  • snake venom or bee venom e.g., from snake venom or bee venom.
  • the phospholipase may be of microbial origin, e.g., from filamentous fungi, yeast or bacteria, such as the genus or species Aspergillus , e.g., A. niger; Dictyostelium , e.g., D. discoideum; Mucor , e.g., M. javanicus, M. mucedo, M.
  • subtilissimus Neurospora , e.g., N. crassa; Rhizomucor , e.g., R. pusillus; Rhizopus , e.g., R. arrhizus, R. japonicus, R. stolonifer; Sclerotinia , e.g., S. libertiana; Trichophyton , e.g., T. rubrum; Whetzelinia , e.g., W. sclerotiorum; Bacillus , e.g., B. megaterium, B. subtilis; Citrobacter , e.g., C.
  • freundii Enterobacter , e.g., E. aerogenes, E. cloacae; Edwardsiella, E. tarda; Erwinia , e.g., E. herbicola; Escherichia , e.g., E. coli; Klebsiella , e.g., K. pneumoniae; Proteus , e.g., P. vulgaris; Providencia , e.g., P. stuartii; Salmonella , e.g., S. typhimurium; Serratia , e.g., S. liquefasciens, S. marcescens; Shigella , e.g., S.
  • the phospholipase may be fungal, e.g., from the class Pyrenomycetes, such as the genus Fusarium , such as a strain of F. culmorum, F. heterosporum, F. solani , or a strain of F. oxysporum .
  • the phospholipase may also be from a filamentous fungus strain within the genus Aspergillus , such as a strain of Aspergillus awamori, Aspergillus foetidus, Aspergillus japonicus, Aspergillus niger or Aspergillus oryzae.
  • Preferred phospholipases are derived from a strain of Humicola , especially Humicola lanuginosa .
  • the phospholipase may be a variant, such as one of the variants disclosed in WO 00/32758, which are hereby incorporated by reference.
  • Preferred phospholipase variants include variants listed in Example 5 of WO 00/32758, which is hereby specifically incorporated by reference.
  • the phospholipase is one described in WO 04/111216, especially the variants listed in the table in Example 1.
  • the phospholipase is derived from a strain of Fusarium , especially Fusarium oxysporum .
  • the phospholipase may be the one concerned in WO 98/026057 displayed in SEQ ID NO: 2 derived from Fusarium oxysporum DSM 2672, or variants thereof.
  • the phospholipase is a phospholipase A 1 (EC. 3.1.1.32). In another preferred embodiment of the invention the phospholipase is a phospholipase A 2 (EC.3.1.1.4.).
  • Examples of commercial phospholipases include LECITASETM and LECITASETM ULTRA, YIELSMAX, or LIPOPAN F (available from Novozymes A/S, Denmark).
  • Amylases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, alpha-amylases obtained from Bacillus , e.g., a special strain of B. licheniformis , described in more detail in GB 1,296,839, or the Bacillus sp. strains disclosed in WO 95/026397 or WO 00/060060.
  • amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, WO 97/43424, WO 01/066712, WO 02/010355, WO 02/031124 and WO 2006/002643 (which references all incorporated by reference.
  • amylases are DURAMYLTM, TERMAMYLTM, TERMAMYL ULTRATM, NATALASETM, STAINZYMETM, STAINZYME ULTRATM, FUNGAMYLTM and BANTM (Novozymes A/S), RAPIDASETM and PURASTARTM (from Genencor International Inc.).
  • Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera Acremonium, Bacillus, Fusarium, Humicola, Pseudomonas , and Thielavia , e.g., the fungal cellulases produced from Fusarium oxysporum, Humicola insolens, Myceliophthora thermophila , and Thielavia terrestris , disclosed in U.S. Pat. Nos. 4,435,307, 5,648,263, 5,691,178, and 5,776,757, WO 89/09259, WO 96/029397, and WO 98/012307.
  • cellulases are the alkaline or neutral cellulases having color care benefits.
  • Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO 98/08940.
  • Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, U.S. Pat. Nos. 5,457,046, 5,686,593, and 5,763,254, WO 95/24471, WO 98/12307 and WO 99/01544.
  • cellulases include CELLUZYMETM, CELLUCLASTTM, CAREZYMETM, ENDOLASETM, RENOZYMETM (Novozymes A/S), CLAZINASETM and PURADAX HATM, ACCELERASETM 1000 (Genencor International Inc.), and KAC-500(B)TM (Kao Corporation).
  • Peroxidases/Oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from Coprinus , e.g., from C. cinereus , and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257.
  • peroxidases include GuardzymeTM and NovozymTM 51004 (Novozymes A/S).
  • Pectate Ivases also called polygalacturonate lyases
  • pectate lyases include pectate lyases that have been cloned from different bacterial genera such as Erwinia, Klebsiella, Pseudomonas , and Xanthomonas , as well as from Bacillus subtilis (Nasser et al., 1993, FEBS Letts. 335:319-326) and Bacillus sp. YA-14 (Kim et al., 1994, Biosci. Biotech. Biochem. 58: 947-949).
  • pectate lyase comprises the amino acid sequence of a pectate lyase disclosed in Heffron et al., 1995, Mol. Plant - Microbe Interact. 8: 331-334 and Henrissat et al., 1995, Plant Physiol. 107: 963-976.
  • pectate lyases are disclosed in WO 99/27083 and WO 99/27084.
  • pectate lyase derived from Bacillus licheniformis is disclosed as SEQ ID NO: 2 in U.S. Pat. No. 6,284,524 (which document is hereby incorporated by reference).
  • Pectate lyase variants are disclosed in WO 02/006442, especially the variants disclosed in the Examples in WO 02/006442 (which document is hereby incorporated by reference).
  • alkaline pectate lyases examples include BIOPREPTM and SCOURZYMETM L from Novozymes A/S, Denmark.
  • Mannanase examples include mannanases of bacterial and fungal origin.
  • the mannanase is derived from a strain of the filamentous fungus genus Aspergillus , preferably Aspergillus aculeatus or Aspergillus niger (WO 94/25576).
  • WO 93/24622 discloses a mannanase isolated from Trichoderma reesei .
  • Mannanases have also been isolated from several bacteria, including Bacillus organisms. For example, Talbot et al., 1990, Appl. Environ. Microbiol.
  • JP-A-03047076 discloses a beta-mannanase derived from Bacillus sp.
  • JP-A-63056289 describes the production of an alkaline, thermostable beta-mannanase.
  • JP-A-63036775 relates to the Bacillus microorganism FERM P-8856 which produces beta-mannanase and beta-mannosidase.
  • JP-A-08051975 discloses alkaline beta-mannanases from alkalophilic Bacillus sp. AM-001.
  • a purified mannanase from Bacillus amyloliquefaciens is disclosed in WO 97/11164.
  • WO 91/18974 describes a hemicellulase such as a glucanase, xylanase or mannanase active.
  • the mannanase may be the alkaline family 5 and 26 mannanases derived from Bacillus agaradhaerens, Bacillus clausii, Bacillus halodurans, Bacillus licheniformis, Bacillus sp., and Humicola insolens disclosed in WO 99/64619.
  • Preferred mannanases are the Bacillus sp. mannanases concerned in the Examples in WO 99/64619 which document is hereby incorporated by reference.
  • mannanases examples include MANNAWAYTM available from Novozymes A/S Denmark.
  • the present invention is also directed to a composition comprising Bacillus amyloliquefaciens strain NRRL B-50154 in an aqueous solution.
  • This composition is designed to provide short- and long-term odor control effects and is environmentally friendly and economical for use.
  • An operable concentration range for Bacillus amyloliquefaciens strain NRRL B-50154 is from about 1 ⁇ 10 5 CFU/ml to 1 ⁇ 10 10 CFU/ml, e.g., from about 1 ⁇ 10 6 CFU/ml to 1 ⁇ 10 3 CFU/ml, with a preferred concentration being about 1 ⁇ 10 3 CFU/ml, such as about 1 ⁇ 10 7 CFU/ml of the formulation.
  • the deodorant compositions of the present invention may further comprise an odor neutralizer, which is an agent that can rapidly interact, by chemical reactions, with odorous compounds to produce odorless compounds. These agents should not rely on the masking mechanism of a perfume to control odors. In addition, these agents must be safe for use and cost effective. Neutralizers must be compatible with the microbial components.
  • the neutralizer is propylene carbonate, which has the molecular formula C 4 H 6 0 3 .
  • a preferred product of propylene carbonate is available from commercial vendors such as Huntsman Chemical Corporation.
  • propylene carbonate can effectively reduce odors, including amine and ammonia odors such as trimethylamine, dimethylamine, and ammonia, which are the major target odorous compounds.
  • propylene carbonate does not inactivate the microbial components even after a long period of contact.
  • odor neutralizing compounds such as sodium citrate, sodium bicarbonate, and sodium carbonate, may also be used in the formulation of this invention.
  • the odor neutralizing is present in an amount of 1-15 wt. %, such as 2-10 wt. % of the composition.
  • Viable microorganisms which are capable of growing on and degrading common domestic, industrial, pet, and animal wastes, capable of surviving the formulations, and compatible with the formulations, and do not produce malodor while performing, may be used in the invention.
  • ingredients may be used in the deodorant compositions of the present invention, including surfactants, fragrances, and dyes.
  • Surfactants can wet and emulsify insoluble waste materials present in the treated system and inclusion of surfactants in the composition of the invention will add to it a cleaning capability. Furthermore, surfactants can be used to break down the insoluble wastes therefore increasing the availability of them to microbial degradation. Suitable surfactants for the invention include nonionic and anionic types. Preferably, the surfactant is present in an amount of 0-8 wt. %, such as 0-6 wt. % of the composition.
  • Fragrance and dye can be optionally added to mask the odor and to control the color of the composition of the invention, respectively, and for market appeal.
  • the fragrance and dye must be compatible with other ingredients of the composition.
  • the present invention is also directed to a drain opener formulation comprising Bacillus amyloliquefaciens strain NRRL B-50154 in an aqueous medium.
  • the drain opener formulation may further comprise surfactant(s) and/or preservative(s).
  • the product has numerous advantages over currently available drain openers; such as activity at pH's closer to neutral, and solubilizing ability for soaps, fats, oils and greases. It further provides for biological activity specific to carbohydrates, and establishes a biofilm in the drains and on downstream surfaces to continuously aid the natural biodegradative process.
  • composition of the present invention comprises a stable suspension of viable microorganisms, surfactant(s), preservatives, and optional fragrances in an aqueous medium with a preferred pH of approximately 5 to 6.
  • An operable concentration range for the microorganisms is from about 1 ⁇ 10 6 CFU/ml to 1 ⁇ 10 9 CFU/ml, with a preferred concentration being about 1 ⁇ 10 8 CFU/ml, such as about 1 ⁇ 10 7 CFU/ml of the formulation.
  • the surfactant in the formulation of the present invention can solubilize grease and make it bioavailable.
  • the surfactant can be any readily biodegradable surfactant, or a mixture of surfactants with low toxicity for the microorganisms contained within the system.
  • the surfactant(s) should have a high grease solubilizing capability.
  • Ionic surfactants or blends of nonionic/ionic surfactants having a hydrophile/lipophile balance approaching 10 are particularly preferred for the necessary grease solubilization.
  • Typical surfactants suitable for use with the present invention include n-alkyl benzene sulfonates and alkyl sulfonates.
  • Preferred nonionic surfactants include aliphatic alcohol alkoxylates, alcohol ethoxylates, polyalkylene oxide copolymers, alkyl phenol alkoxylates, carboxylic acid esters, carboxylic amides, and others.
  • the surfactant is present in a concentration from about 3 to 10 wt. %.
  • the pH of the solution should be maintained as near as possible to neutral to insure adequate bacterial activity, and to minimize health risk, but be in a range compatible for surfactant activity and conducive to the survival of the bacteria.
  • An operable pH range can be between about 3 to 10.
  • a preservative such as paraben, methyl paraben, or 1,2-benzisothiazolin-3-one is added to inhibit or prevent the growth of undesirable microbial contaminants in the product.
  • the necessity for a preservative is greatest when the pH is near neutral, and the least when the pH is at the extreme ends of the operable range.
  • the concentration of the preservative is determined by the vendor's recommendations.
  • a typical concentration range for the preservative used in the example is from about 0.075 to 0.75 weight percent.
  • Methyl anthranilate in concentrations of from about 25 to 50 ppm (w/v) by weight has been found to be a satisfactory additive.
  • a chelating agent is added to enhance stabilization of the formulation.
  • a fragrance can optionally be added to mask the odor of the product components, and for market appeal.
  • the fragrance must be compatible with the other components of the formulation.
  • the present invention also relates to sanitizer formulations comprising Bacillus amyloliquefaciens strain NRRL B-50154.
  • the formulations comprise a suspension of a sanitizing composition, bacterial spores, and surfactants all contained in an aqueous solution.
  • Sanitizing agents or composition and disinfectants belong to the same category of antimicrobial (active) ingredient.
  • Antimicrobial (active) ingredients are compounds that kill microorganisms or prevent or inhibit their growth and reproduction and that contribute to the claimed effect of the product in which it is included. More specifically, a sanitizer is an agent that reduces the number of microbial contaminants or pathogens to safe levels as judged by public health requirements.
  • the surfactant component functions to clean the surface by removing the soil, dirt, dried urine and soap and helps in sanitizing the surface.
  • the sanitizing composition sanitizes the surface (kills pathogens) and preserves the formulation from contamination by unwanted microorganisms.
  • the bacterial spores and vegetative cells function to seed the waste collection system, control odor and provide a healthy dominant microbial population that inhibits the growth of pathogens through substrate competition, production of antibiotics, etc.
  • the composition comprises 1,2-benzisothiazolin-3-one (Proxel), tetrasodium ethylenediaminetetraacetate (EDTA), and isopropyl alcohol (IPA) at a selected range of concentrations, combined with other components of the formula, can effectively inactivate indicator organisms.
  • This sanitizing composition preferably is at neutral pH and does not contain chlorine-related materials, which are commonly used as sanitizers. Consequently, this sanitizing composition is more environmentally friendly and less or not corrosive.
  • the formulation When the formulation is applied to a bathroom fixture, sink, toilet bowl, etc., it can be sprayed or squeezed out of a container directly onto a surface or brush. The formulation is then left on the surface or scoured against the surface with a brush for not less than 10 minutes. The product is then flushed or rinsed with water and discharged from the fixture.
  • the formulations of the invention contain sanitizing agents, bacterial spores, and surfactants. Fragrance and dye are also added to control smell and color of the formulations, respectively.
  • the formulation can optionally contain an abrasive. While the key components remain the same, different thickening agents might be used in the formulation with and without an abrasive.
  • sanitizing agents can be used for inactivating pathogens on surfaces, not all of them can be used in the present invention. This is because the sanitizing agents used in this invention are not only required to inactivate pathogens effectively, but must not have negative effects on the stability and activity of the bacterial spores contained in the formulation. In addition, the sanitizing agents are required to be relatively friendly to the environment, and should not cause skin sensitization, and should not corrode the construction materials of the fixtures on which they are used.
  • the sanitizing composition is composed of Proxel, EDTA, and IPA at selected ranges of concentrations.
  • the maximum concentration of Proxel not likely to cause skin sensitization is about 2,900 mg/L.
  • the suitable concentration ranges of Proxel, Versene (Versene contains 39% EDTA), and IPA are 0.087 to 0.29% (vol.), 0.36 to 1.19% (vol.), and 3.5 to 7% (vol.), respectively.
  • An additional compound, methyl anthranilate may also be used in the formulations of the invention. The purpose of using methyl anthranilate is to assist in preservation of the formulations.
  • sanitizing agents such as quaternary ammonium compounds (QACs), nitro-containing organosulfur and sulfur-nitrogen compounds, may also be used in the formulation of this invention.
  • QACs quaternary ammonium compounds
  • nitro-containing organosulfur and sulfur-nitrogen compounds may also be used in the formulation of this invention.
  • An operable concentration range for the microorganisms is from 1 ⁇ 10 5 to 1 ⁇ 10 9 CFU/ml, such as 10 7 CFU/ml of the formulation.
  • Surfactants are also an essential component in the sanitizer formulations of the present invention.
  • the surfactants can wet and emulsify soil, including dirt, dried urine, soap, etc., present on a dirty surface.
  • surfactants aid in the sanitization of the surface.
  • the surfactants used in the present invention have low toxicity for the microorganisms contained within the formulation. A single surfactant or a blend of several surfactants can be used.
  • Nonionic surfactants are generally preferred for use in the compositions of the present invention since they provide the desired wetting and emulsification actions and do not significantly inhibit spore stability and activity.
  • Nonionic surfactants are surfactants having no electrical charge when dissolved or dispersed in an aqueous medium.
  • Preferred nonionic surfactants include aliphatic alcohol alkoxylates, alcohol ethoxylates, polyalkylene oxide copolymers, alkyl phenol alkoxylates, carboxylic acid esters, carboxylic amides, and others.
  • Anionic surfactants or mixtures of anionic and nonionic surfactants may also be used in the formulations of the invention.
  • Anionic surfactants are surfactants having a hydrophilic moiety in an anionic or negatively charged state in aqueous solution.
  • Commonly available anionic surfactants include sulfonic acids, sulfuric acid esters, carboxylic acids, and salts thereof.
  • Abrasives are water-insoluble solid particles.
  • the purpose of using abrasives is to provide deep scouring and cleaning.
  • abrasives may be optionally used in the formulation of the invention.
  • Suitable abrasives include calcium carbonate, magnesium carbonate, silica, etc.
  • the preferred particle size of the abrasive ranges from about 90 to 325 mesh.
  • a thickening agent needs to be used in this invention to suspend the spores.
  • Suitable aqueous thickening agents include: polyacrylic acid, polystyrene, polyvinyl alcohol, polypropylene, etc.
  • a preferred thickening agent for suspending bacterial spores is polyacrylic acid (e.g., Acrysol TT615 from Rohm and Haas Co.). If an abrasive is used in the formulation, thickening agents in addition to polyacrylic acid might be needed to maintain the suspension of the abrasive.
  • a fragrance and a dye can be optionally added to mask the odor and to control the color of the product components, respectively, and for market appeal.
  • the fragrance and dye must be compatible with the other components of the formulation.
  • a Bacillus amyloliquefaciens strain was deposited under the terms of the Budapest Treaty on Jul. 24, 2008 with the Agricultural Research Service Culture Collection, 1815 North University Street, Peoria, Ill. 61604, U.S.A., under accession number NRRL B-50154.
  • the deposit shall be maintained in viable condition at the depository during the entire term of the issued patent and shall be made available to any person or entity for non-commercial use without restriction, but in accordance with the provisions of the law governing the deposit.
  • Chemicals used as buffers and reagents were commercial products of at least reagent grade.
  • Enzyme production medium is used according to the following recipe: Base Media (all values in g/L unless otherwise noted)
  • the components are mixed in DI water and autoclaved for 20 minutes.
  • Alpha-amylases (1,4- ⁇ -D-glucanohydrolases, E.C. 3.2.1.1) catalyze the hydrolytic degradation of polymeric carbohydrates such as amylose, amylopectin and glycogen by cleaving 1,4-alpha-glucosidic bonds.
  • polymeric carbohydrates such as amylose, amylopectin and glycogen
  • alpha-glucosidic bonds In polysaccharides and oligosaccharides, several glycosidic bonds are hydrolyzed simultaneously. Maltotriose, the smallest such unit, is converted into maltose and glucose, albeit very slowly.
  • the kinetic method described here is based on the well-proven cleavage of 4,6-ethylidene-(G 7 )-1,4-nitrophenyl-(G1)- ⁇ ,D-maltoheptaoside by alpha-amylase and subsequent hydrolysis of all the degradation products to p-nitrophenol with the aid of alpha-glucosidase. This results in 100% liberation of the chromophore.
  • oligosaccharides are cleaved under the catalytic action of alpha-amylases.
  • the resulting PNP derivatives are cleaved directly to PNP by the action of alpha-glucosidase and the color intensity of the p-nitrophenol formed is directly proportional to the alpha-amylase activity and is measured spectrophotometrically.
  • Reaction (1) is mediated by the amylase added from the standard or sample.
  • Reaction (2) is mediated by the glucosidase provided in the kit.
  • BAN is an alpha-amylase available from Novozymes.
  • the samples should be diluted such that the final slopes read from the Konelab are between 0.05 and 0.50 to make sure that the experimental samples fall within the scope of the standard curve.
  • Bacillus amyloliquefaciens strain NRRL B-50154 and Bacillus amyloliquefaciens strain SB3282 were grown in buffered plate count broth (BPCB: 17 g m-Plate Count Broth, 20 ml of pH 7 buffer made with 1 part 9.078 g/L KH 2 PO 4 and 1.5 parts 9.476 g/L of K 2 HPO 4 , pH adjusted to 7) to a density of approximately 0.2 absorbance units at 590 nm wavelength. 100 microliters of each culture were delivered to wells of a 96 well BD Oxygen Biosensor microtiter plate (Catalog #353830, BD Lifesciences, San Jose, Calif.).
  • the cultures were diluted in additional BPCB and 0.01 ⁇ dilutions of the cultures were delivered to additional wells of the same plate.
  • Each dilution of bacterial culture received 100 microliters of five different concentrations of phage challenge as follows: 1 ⁇ ( ⁇ 10 10 pfu/ml), 0.1 ⁇ , 0.01 ⁇ , 0.001 ⁇ , and 0.0001 ⁇ .
  • the diluent for the phage was BPCB.
  • One well of each bacterial culture dilution received 100 microliters of plain BPCB instead of phage and thus served as the control well.
  • BD Oxygen Biosensor microtiter plates contain an oxygen sensitive fluorophore that fluoresces when the cell culture in the well consumes oxygen and thus fluorescence intensity correlates to culture growth rates and general health. Data was analyzed by comparing the fluorescent O 2 consumption curves of Bacillus amyloliquefaciens strain NRRL B-50154 to the Bacillus amyloliquefaciens strain SB3282 at the various bacteria and phage ratios.
  • Bacillus amyloliquefaciens strain NRRL B-50154 outperformed Bacillus amyloliquefaciens strain SB3282 in this way at multiple cell and phage densities examined. At 1 ⁇ cell culture concentration, Bacillus amyloliquefaciens strain SB3282 showed long lag periods prior to growth at most phage concentrations tested, whereas Bacillus amyloliquefaciens strain NRRL B-50154 showed a short lag followed by ample and prolonged proliferation.
  • Bacillus amyloliquefaciens strain SB3282 completely succumbed to phage pressure at most phage concentrations tested, whereas Bacillus amyloliquefaciens strain NRRL B-50154 showed ample and prolonged proliferation at all phage concentrations.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biomedical Technology (AREA)
  • Dentistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
US12/511,499 2008-07-30 2009-07-29 Bacillus Amyloliquefaciens Strain Abandoned US20100028314A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/511,499 US20100028314A1 (en) 2008-07-30 2009-07-29 Bacillus Amyloliquefaciens Strain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8472808P 2008-07-30 2008-07-30
US12/511,499 US20100028314A1 (en) 2008-07-30 2009-07-29 Bacillus Amyloliquefaciens Strain

Publications (1)

Publication Number Publication Date
US20100028314A1 true US20100028314A1 (en) 2010-02-04

Family

ID=41608593

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/511,499 Abandoned US20100028314A1 (en) 2008-07-30 2009-07-29 Bacillus Amyloliquefaciens Strain

Country Status (2)

Country Link
US (1) US20100028314A1 (fr)
WO (1) WO2010014715A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100308214A1 (en) * 2009-06-04 2010-12-09 Zena Technologies, Inc. Array of nanowires in a single cavity with anti-reflective coating on substrate
US20110199057A1 (en) * 2010-02-17 2011-08-18 Texas Instruments Incorporated Battery protection circuit and method for energy harvester circuit
US8236549B2 (en) 2010-05-04 2012-08-07 Novozymes Biologicals, Inc. Bacillus amylollquefaciens strain
DE102014220554A1 (de) 2014-10-10 2016-04-14 BSH Hausgeräte GmbH Verfahren zur Bekämpfung von Mikroorganismen in einem wasserführenden Haushaltsgerät und hierfür geeignetes Haushaltsgerät
WO2016097857A1 (fr) * 2014-12-15 2016-06-23 Gfs Corporation Aus Pty Ltd Compositions et leurs procédés d'utilisation
EP3415596A1 (fr) * 2017-06-16 2018-12-19 The Procter & Gamble Company Composition de traitement de surface comprenant un consortium microbien pour la suppression de micro-organismes non-gras sur une surface
BE1025484B1 (fr) * 2017-12-08 2019-03-15 Ets Pollet Sa Composition détergente
DE102020108490A1 (de) 2020-03-27 2021-09-30 Mösslein Gmbh Verfahren zur Vorbehandlung von einer Nutzwasserleitungsvorrichtung

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660645C (fr) 2006-08-11 2016-04-05 Novozymes Biologicals, Inc. Cultures de bacilles pour utilisation dans le lavage, le nettoyage,l'elimination des taches ou la degradation des dechets
WO2012112718A1 (fr) 2011-02-15 2012-08-23 Novozymes Biologicals, Inc. Réduction des odeurs dans les machines de nettoyage et les procédés de nettoyage
ES2397333B1 (es) * 2011-08-31 2014-01-16 Betelgeux, S.L. Composición marcadora de biofilms y método de detección de los mismos en superficies.
CN107613767B (zh) * 2015-04-09 2022-06-21 Isp投资有限公司 协同防腐组合物
CN105753142B (zh) * 2016-04-18 2019-03-26 南京大学 一种曝气生物滤池填料生物膜的原位活化剂及原位活化方法
KR101920557B1 (ko) * 2016-11-29 2018-11-20 재단법인 전라북도생물산업진흥원 음식물 쓰레기 분해용 혼합균주 및 이를 이용한 음식물 쓰레기 처리 방법
CN108823119A (zh) * 2018-05-31 2018-11-16 深圳市微米生物技术有限公司 一种解淀粉芽孢杆菌及菌剂和其在处理餐厨垃圾中的应用
FR3118058B1 (fr) 2020-12-22 2025-05-23 H T S Bio Souche de bacillus pumilus presentant un fort antagonisme vis-a-vis de pathogenes de surface

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171591A (en) * 1990-05-03 1992-12-15 The United States Of America As Represented By The Secretary Of Agriculture Control or elimination of undesirable bacteria using parasitic Bdellovibrio bacteria
US5242593A (en) * 1988-12-09 1993-09-07 Oberkofler Joerg Method for reducing the build-up of slime and/or film in water circulation systems
RU2003689C1 (ru) * 1992-03-30 1993-11-30 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Рекомбинантна плазмидна ДНК рВА1418, кодирующа альфа-амилазу BACILLUS AMYLOLIQUEFACIENS и штамм-бактерий BACILLUS AMYLOLIQUEFACIENS - продуцент альфа-амилазы BACILLUS AMYLOLIQUEFACIENS
US5360517A (en) * 1992-02-24 1994-11-01 Texel Bacterial disinfection of flora-contaminated papermaking process streams
US5863882A (en) * 1996-01-16 1999-01-26 Sybron Chemical Holdings, Inc. Cleaner and sanitizer formulation
US20080057670A1 (en) * 2003-05-28 2008-03-06 Kim Jung H Semiconductor Device and Method of Fabricating the Same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103181400B (zh) * 2004-09-10 2016-08-10 诺维信北美公司 防止、去除、减少或破坏生物膜的方法
CA2660645C (fr) * 2006-08-11 2016-04-05 Novozymes Biologicals, Inc. Cultures de bacilles pour utilisation dans le lavage, le nettoyage,l'elimination des taches ou la degradation des dechets

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242593A (en) * 1988-12-09 1993-09-07 Oberkofler Joerg Method for reducing the build-up of slime and/or film in water circulation systems
US5171591A (en) * 1990-05-03 1992-12-15 The United States Of America As Represented By The Secretary Of Agriculture Control or elimination of undesirable bacteria using parasitic Bdellovibrio bacteria
US5360517A (en) * 1992-02-24 1994-11-01 Texel Bacterial disinfection of flora-contaminated papermaking process streams
RU2003689C1 (ru) * 1992-03-30 1993-11-30 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Рекомбинантна плазмидна ДНК рВА1418, кодирующа альфа-амилазу BACILLUS AMYLOLIQUEFACIENS и штамм-бактерий BACILLUS AMYLOLIQUEFACIENS - продуцент альфа-амилазы BACILLUS AMYLOLIQUEFACIENS
US5863882A (en) * 1996-01-16 1999-01-26 Sybron Chemical Holdings, Inc. Cleaner and sanitizer formulation
US20080057670A1 (en) * 2003-05-28 2008-03-06 Kim Jung H Semiconductor Device and Method of Fabricating the Same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Translation of RU 2003689 (translated June 2012) *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100308214A1 (en) * 2009-06-04 2010-12-09 Zena Technologies, Inc. Array of nanowires in a single cavity with anti-reflective coating on substrate
US20110199057A1 (en) * 2010-02-17 2011-08-18 Texas Instruments Incorporated Battery protection circuit and method for energy harvester circuit
US8236549B2 (en) 2010-05-04 2012-08-07 Novozymes Biologicals, Inc. Bacillus amylollquefaciens strain
DE102014220554A1 (de) 2014-10-10 2016-04-14 BSH Hausgeräte GmbH Verfahren zur Bekämpfung von Mikroorganismen in einem wasserführenden Haushaltsgerät und hierfür geeignetes Haushaltsgerät
WO2016097857A1 (fr) * 2014-12-15 2016-06-23 Gfs Corporation Aus Pty Ltd Compositions et leurs procédés d'utilisation
EP3415596A1 (fr) * 2017-06-16 2018-12-19 The Procter & Gamble Company Composition de traitement de surface comprenant un consortium microbien pour la suppression de micro-organismes non-gras sur une surface
EP3415595A1 (fr) * 2017-06-16 2018-12-19 The Procter & Gamble Company Composition de traitement de surface comprenant un consortium microbien pour la suppression de micro-organismes non-gras sur une surface
WO2018232087A1 (fr) * 2017-06-16 2018-12-20 The Procter & Gamble Company Composition de traitement de surface comprenant un consortium microbien permettant de supprimer des micro-organismes non gras sur une surface
BE1025484B1 (fr) * 2017-12-08 2019-03-15 Ets Pollet Sa Composition détergente
WO2019110811A1 (fr) 2017-12-08 2019-06-13 Ets Pollet S.A. Composition detergente
DE102020108490A1 (de) 2020-03-27 2021-09-30 Mösslein Gmbh Verfahren zur Vorbehandlung von einer Nutzwasserleitungsvorrichtung

Also Published As

Publication number Publication date
WO2010014715A1 (fr) 2010-02-04

Similar Documents

Publication Publication Date Title
US20100008893A1 (en) Bacillus velezensis strain
US20100028314A1 (en) Bacillus Amyloliquefaciens Strain
US9809477B2 (en) Preventing and reducing biofilm formation and planktonic proliferation
EP2066785B1 (fr) Cultures bacteriennes et compositions contenant des cultures bacteriennes
JP6480397B2 (ja) 洗濯機又は洗濯工程における匂いの緩和
US20090324533A1 (en) Bacillus amyloliquefaciens Strain
CA2798504A1 (fr) Souche de bacillus amyloliquefaciens
US20150164087A1 (en) Bacillus Subtilis Strain

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVOZYMES A/S,DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SNYDER, AMY;REEL/FRAME:023115/0889

Effective date: 20090810

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION